Wearable Drug Delivery Devices: Manufacturing and Regulatory Challenges
Aligning advanced user-driven mechanical injectors with federal compliance criteria requires a highly disciplined validation baseline. This in-depth industry guide examines the core engineering and design challenges encountered during the scale-up of wearable drug delivery devices. Learn how international cross-functional teams manage component tolerances, monitor micro-fluidic tracks, and pass inspections in 2026.
Recent FDA Warning Letter Trends in Sterile Drug Manufacturing
Aligning commercial aseptic plants with current regulatory standards demands a highly disciplined risk management baseline. This strategic executive analysis examines the critical validation gaps highlighted across recent FDA warning letters sterile manufacturing filings. Discover how international operations groups correct environmental faults, optimize barrier isolation loops, and maintain secure documentation setups in 2026.
Latest Articles
View All ArticlesInternational
Biologics
Pharmaceuticals
Logistics & Supply Chain
AI & Automation
Quality & Regulatory
News Capsules
— weekly intelligence in 60 seconds
Evotec and Sandoz Explore $300M Biologics Unit Sale in Toulouse: CDMO Capacity Shifts
Evotec has entered a non-binding agreement with Sandoz to explore the $300M sale of its Toulouse biologics facility, signaling shifts in CDMO capacity and outsourcing dynamics.
Read Full Story- Biotech – June 8, 2026 The Biggest Downstream Purification Bottlenecks in Biologics Manufacturing
- Pharmaceuticals – June 18, 2026 High Potency API Manufacturing: Containment Requirements Sponsors Must Understand
- Supply Chain and Logistics – June 12, 2026 Shipping Lane Qualification Explained for Global Pharmaceutical Supply Chains
Latest Expert Post
Direct-to-Patient Shipments: What I Said in 2021 — and What We See in 2026
Developing biosimilars involves navigating complex manufacturing and regulatory challenges that go far beyond traditional generics. This guide explores key hurdles—from analytical characterization to large-scale production—and highlights how strategic CDMO partnerships help ensure similarity, scalability, and commercial success.
Read Full Post
Cold Chain Logistics in Biologics Manufacturing: Preventing Temperature Excursions
Maintaining the integrity of temperature-sensitive therapies is the greatest challenge in modern medicine. This guide explores how cold chain logistics biologics manufacturing protocols prevent temperature excursions, utilize real-time monitoring, and ensure regulatory compliance. Learn about specialized packaging, risk mitigation strategies, and the role of CDMOs in securing the global supply chain.
Adventitious Agent Testing in Biologics: Building a CDMO Testing Strategy That Regulators Accept
Protecting biologics from viral, bacterial, and fungal contaminants is a regulatory mandate. This 2,500-word guide details Adventitious Agent Testing strategies at CDMOs. Explore in vitro and in vivo assays, Next-Generation Sequencing (NGS) trends, and how to structure your testing program to ensure safety and clinical success.
Original Video Programming
Executive interviews, fill-finish features, and field intelligence from inside CDMO facilities.
Leadership Video Interview Series
Candid conversations with the CEOs, COOs, and CSOs redefining contract manufacturing.
Field Intelligence Reports
Boots-on-the-ground dispatches from inside CDMO facilities and pilot lines.
Now: Craig Mooney from CDSG.
Pharma Problem Solved
Actionable solutions in small doses — short-form expert answers.
Latest: Dr. Frank Gibson on aseptic scale-up.
Inside the Facility — CDMO Walkthrough
Want your facility featured next?
Put your capabilities in front of sponsors actively shopping for a CDMO partner.
Events to Attend
View All Events
Bio International Convention
ChemOutsourcing
CDMOworld Weekly Live Broadcast
15-Minute Industry Wrap-Up
A fast, focused live video broadcast covering the most important moves across the CDMO landscape — deals, capacity, regulatory shifts, and the people behind them.